Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-921352 in Adults With Focal Onset Seizures
NCT05159908Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of zandatrigine in focal onset seizure, sponsored by Neurocrine Biosciences. Started Nov 2021; status: completed.
02
Drugs
zandatrigine
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT05159908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159908.